Abiopharma

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Fresenius Medical Care Again Named to Top 100 Women-Led Businesses in Massachusetts

Incyte maakt nieuwe gegevens bekend uit fase 3b TRuE-AD4-onderzoek naar Opzelura® (ruxolitinibcrème) bij volwasssen met matige atopische dermatitis

NRC Health Announces Third Quarter 2025 Results

Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AngioDynamics to Participate in the UBS Global Healthcare Conference

Agilent Names Adam S. Elinoff as Chief Financial Officer

Dexcom Appoints Euan Ashley to Board of Directors

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025